FY2025 EPS Estimates for BrainsWay Decreased by Analyst

BrainsWay Ltd. (NASDAQ:BWAY) – Research analysts at HC Wainwright cut their FY2025 EPS estimates for BrainsWay in a note issued to investors on Monday, October 21st. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.07 per share for the year, down from their prior forecast of $0.16. HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for BrainsWay’s current full-year earnings is $0.06 per share.

BrainsWay (NASDAQ:BWAY) last issued its earnings results on Tuesday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter. BrainsWay had a net margin of 1.67% and a return on equity of 1.45%. The company had revenue of $10.01 million for the quarter, compared to analysts’ expectations of $9.40 million. During the same quarter last year, the company posted ($0.05) earnings per share.

Separately, Northland Securities boosted their price objective on shares of BrainsWay from $11.00 to $12.50 and gave the company an “outperform” rating in a research report on Thursday, October 3rd.

BrainsWay Stock Performance

BWAY stock opened at $9.55 on Wednesday. The company has a market capitalization of $159.15 million, a PE ratio of -106.11 and a beta of 1.26. The company’s fifty day moving average price is $8.51 and its 200-day moving average price is $6.92. BrainsWay has a one year low of $3.09 and a one year high of $10.61.

Institutional Trading of BrainsWay

Several hedge funds have recently modified their holdings of BWAY. Acadian Asset Management LLC raised its position in BrainsWay by 583.2% during the 1st quarter. Acadian Asset Management LLC now owns 175,416 shares of the company’s stock worth $923,000 after buying an additional 149,740 shares during the last quarter. Essex Investment Management Co. LLC grew its stake in shares of BrainsWay by 37.5% during the 1st quarter. Essex Investment Management Co. LLC now owns 324,843 shares of the company’s stock worth $1,718,000 after purchasing an additional 88,593 shares during the period. Good Life Advisors LLC grew its stake in shares of BrainsWay by 65.5% during the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock worth $516,000 after purchasing an additional 22,080 shares during the period. Perritt Capital Management Inc acquired a new stake in shares of BrainsWay during the 2nd quarter worth approximately $121,000. Finally, Virtu Financial LLC acquired a new stake in shares of BrainsWay during the 1st quarter worth approximately $60,000. 30.11% of the stock is owned by hedge funds and other institutional investors.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.